The pharmacokinetics of ofloxacin were investigated in eight healthy male volunteers. A single infusion (200 mg over 0.5 h) was performed on day 1, followed by a washout period of 2 weeks. Repeated administrations were performed for 4 days (200 mg every 12 h). Pharmacokinetic parameters were determined from the plasma decay curves of the single and the last of the multiple administrations. Ofloxacin kinetics after the single dose were best described by a two-phase curve with a total body clearance of 241.6 After written informed consent and national and local ethical committee approval had been obtained, eight healthy male subjects with no known allergy to quinolone derivatives were impaneled. They had normal hepatic and renal functions. They ranged in age from 21 to 27 years (mean + standard deviation, 23.9 + 2.3 years) and in body weight from 65 to 89 kg (mean ± standard deviation, 72.9 ± 8.0 kg). None of the subjects had taken any medication for at least 1 week prior to the study. Alcohol and tobacco were prohibited during the study.
Ofloxacin is a new fluoroquinolone carboxylic acid derivative with a broad spectrum of activity against gram-negative and gram-positive microorganisms (8) . The pharmacokinetics of the oral form of this compound have been extensively studied in various situations in humans (3, 9; S. C. Flor (Cmi,,) and at the end of the infusion time (Cmax). After the last infusion, additional blood and urine samples were obtained according to the schedule described for the first step. Before and at the end of the study, the subjects underwent a complete physical examination and laboratory testing. Urine analysis included testing for creatinine clearance (CLCR), excretion of Nacetyl-glucosaminidase, glutamyltransferase, and 12-microglobulin. The presence of abnormal crystalluria was assessed at the end of the multiple-dose regimen with reference to pretherapy samples. The subjects were also questioned daily about any drug-induced side effects.
Samples were stored at -20°C and assayed within 2 weeks.
Ofloxacin concentrations in serum and urine were measured by ion-paired reversed-phase liquid chromatography with fluorimetric detection by the (Fig. 1) .
Ofloxacin was well distributed in the body at 112.0 ± 22.8 liters. V appeared not to be modified after the last administration. Total body clearance was 241.6 ± 43.3 ml min-' at the first infusion and was not modified after the last infusion (Table 1) .
Ofloxacin was mainly excreted by the kidneys, since the unchanged excreted fraction was 65.8 ± 8.4% of the administered dose, yielding an apparent CLR of 157.5 ml min-' 1.73 m-2. The CLR values were always higher than the CLCR of the subjects (Table 1) . After multiple infusions of ofloxacin (200 mg twice a day), the Cmax ranged from 4.0 to 4.49 mg ml-1, whereas the Cmin ranged from 0.34 to 0.56 mg ml-', and the plateau was reached immediately upon the second administration (no significant difference between the Cmin values) (Fig. 1) .
The data in the literature dealing with i.v. pharmacokinetics of ofloxacin in healthy volunteers are limited. Lode et al. When twice-daily oral doses were given for several days, Ichihara et al. (5) and Dragosa et al. (2) reported an accumulation factor of about 1.3, with an increase in the elimination half-life of about 20%, which could account for this observation (8) . Our study was designed to evaluate, after repeated i.v. infusions, a possible modification of the main pharmacokinetic parameters which could yield an abnormal accumulation of ofloxacin. Our data demonstrate that the AUC after the single infusion does not significantly differ from the AUCO12 obtained after the last infusion (at steady state) and that the theoretical accumulation factor, calculated with a mean t1/2, of 5.37 h and a dosing interval of 12 h (r = 1.28), is even higher than the actual mean accumulation factor estimated by the AUC ratio (r = 0.98 + 0.23). In addition, the observed Cmin + standard deviation remained within the range of the simulation (Fig. 1) . We thus conclude that this dosing interval does not modify the pharmacokinetic profile of ofloxacin. If one compares the concentrations in serum obtained after i.v. infusion and oral intake of the same 200-mg dose of ofloxacin, it is seen that the Cmax is approximately twofold higher at the end of the infusion (30 min) than 1 or 2 h after the oral dose (Tmax). This point may be clinically relevant given the fact that the antibacterial effect of the fluoroquinolones is mainly concentration dependent. In this study, the i.v. formulation of ofloxacin was well tolerated (no side effects reported), and it appears that this parenteral presentation (alone or in combination with other antibiotics) may be useful in the initial therapy of severe infections caused by susceptible microorganisms. A 12-h dosing interval seems appropriate.
